Mounjaro and Migraines: Can Weight Loss on Tirzepatide Reduce Migraine Attacks?

Mounjaro and migraines are attracting growing attention from neurologists and obesity specialists alike. While tirzepatide is licensed for weight management and type 2 diabetes, emerging clinical evidence suggests that GLP-1 receptor agonists may also reduce the frequency and severity of migraine attacks. For patients living with both obesity and chronic migraine, this represents a potentially significant secondary benefit of treatment.

At CutKilo, our doctor-led clinic at 86 Harley Street regularly sees patients who report improvements in headache patterns during Mounjaro treatment. In this article, we examine what the latest research says about tirzepatide and migraine prevention, explain the biological mechanisms that may link obesity to migraine, and outline what patients can realistically expect. For general information about headaches as a side effect of treatment, see our separate guide on headaches on Mounjaro.

Possibly. A 2025 case series published in Headache: The Journal of Head and Face Pain reported that two patients with migraine experienced meaningful reductions in attack frequency after starting tirzepatide. Separately, a pharmacoepidemiological analysis of over 16 million FDA adverse event reports found that GLP-1 receptor agonist use was inversely associated with migraine reporting. However, Mounjaro is not licensed for migraine prevention, and the evidence remains preliminary. The observed benefits may stem partly from weight loss itself, which is an independent risk modifier for migraine.

Obesity and migraine share a well-documented epidemiological relationship. Population-based studies have consistently shown that both total body obesity and abdominal obesity are associated with a higher prevalence of migraine. Moreover, the relationship appears to be dose-dependent: the higher the BMI, the greater the frequency of attacks and the higher the risk of migraine becoming chronic (defined as 15 or more headache days per month).

Several biological pathways explain this link. Excess adipose tissue promotes chronic systemic inflammation by releasing pro-inflammatory cytokines, including interleukin-6 and tumour necrosis factor-alpha. These mediators sensitise the trigeminal pain pathways that underlie migraine. In addition, obesity is associated with insulin resistance, which impairs cerebrovascular regulation and can lower the threshold for cortical spreading depression, the electrical wave believed to trigger migraine aura.

Furthermore, adipose tissue produces adipokines such as leptin in excess, while adiponectin levels tend to fall. This hormonal imbalance has been implicated in both pain sensitisation and neurogenic inflammation. Consequently, weight reduction has the potential to interrupt multiple migraine-promoting pathways simultaneously.

The most specific evidence for tirzepatide and migraine comes from a case series by Shah and colleagues, published in Headache in 2025. The study documented two patients with chronic or high-frequency episodic migraine who experienced clinically meaningful reductions in monthly headache days after starting tirzepatide for weight management. The authors noted that both patients also lost weight, which is a significant confounding factor, but argued that the rapidity and magnitude of improvement warranted further investigation into a possible direct effect.

In a broader context, a pilot cohort study of liraglutide (another GLP-1 receptor agonist) in patients with obesity and chronic migraine found that mean monthly headache days fell from 19.8 at baseline to 10.7 following treatment. This represents a clinically significant reduction of over nine days per month. While liraglutide and tirzepatide are different molecules, they share the GLP-1 receptor agonist mechanism that appears to be relevant to migraine pathophysiology.

Additionally, a large-scale pharmacoepidemiological analysis of the FDA Adverse Event Reporting System (covering over 16 million reports from 2004 to 2024) found an inverse association between GLP-1 receptor agonist use and migraine reporting. This finding was independently replicated in the Japanese JADER pharmacovigilance database, strengthening the signal.

The biological mechanisms linking GLP-1 receptor activation to migraine prevention are an active area of research. Several pathways have been identified in preclinical studies.

First, GLP-1 receptor agonists have been shown to reduce expression of calcitonin gene-related peptide (CGRP) in experimental migraine models. CGRP is the primary neuropeptide implicated in migraine pathogenesis, and the entire newest class of preventive migraine medications (including erenumab, fremanezumab and galcanezumab) works by blocking CGRP or its receptor. If tirzepatide reduces CGRP levels as a secondary effect, this could contribute to migraine prevention through the same pathway targeted by dedicated anti-CGRP therapies.

Second, GLP-1 receptor activation in the trigeminal nucleus caudalis (the brainstem relay station for head and face pain) suppresses microglial activation and reduces pro-inflammatory cytokine release, including interleukin-1 beta and tumour necrosis factor-alpha. This anti-neuroinflammatory action may directly raise the threshold for migraine initiation.

Third, tirzepatide reduces intracranial pressure. Research on idiopathic intracranial hypertension (a condition characterised by raised cerebrospinal fluid pressure and severe headache, often associated with obesity) has shown that tirzepatide significantly reduces intracranial pressure. Lower intracranial pressure reduces compression of intracranial venous sinuses, which in turn may decrease the release of CGRP and other pain-promoting molecules.

It is important to be clear: Mounjaro is not a migraine medication and should not be prescribed as one. Patients with frequent or severe migraines should be assessed and treated by a neurologist or headache specialist using established preventive therapies.

Current NICE-recommended preventive options for migraine include topiramate, propranolol, amitriptyline and, for eligible patients, anti-CGRP monoclonal antibodies. These medications have been evaluated in large randomised controlled trials and have well-characterised efficacy and safety profiles.

However, for patients who have both obesity and migraine, the potential dual benefit of tirzepatide is worth discussing with their medical team. Notably, topiramate (one of the most widely used migraine preventives) also causes weight loss as a side effect, which suggests that the neurological and metabolic benefits of weight reduction in migraine are recognised within conventional treatment approaches.

Patients starting Mounjaro for weight loss who also experience migraines should be aware of several practical considerations.

In the first few weeks of treatment, some patients experience headaches as a side effect of tirzepatide itself, typically related to changes in blood sugar or mild dehydration. These early headaches are usually self-limiting and resolve as the body adjusts. They are distinct from migraine and should not be confused with a worsening of underlying migraine disease.

As weight loss progresses (typically from month two onwards), patients with obesity-related migraine may begin to notice a reduction in attack frequency or severity. The improvement is likely to be gradual and proportional to the degree of weight lost and the extent of metabolic improvement. For more on how tirzepatide addresses systemic inflammation, see our article on Mounjaro and inflammation.

Patients should continue any existing migraine preventive medications unless advised otherwise by their neurologist. Mounjaro should be viewed as a potential complementary benefit rather than a replacement for established migraine treatment.

Does Mounjaro cause migraines? No. Migraine is not listed as a side effect of tirzepatide in the MHRA Summary of Product Characteristics. Some patients experience mild headaches in the early weeks of treatment (reported in approximately 5 to 10 per cent of trial participants), but these are typically tension-type headaches related to blood sugar adjustment or dehydration, not migraines.

Can I take Mounjaro alongside my migraine medication? In most cases, yes. There are no known pharmacological interactions between tirzepatide and common migraine preventives (topiramate, propranolol, amitriptyline) or acute treatments (triptans, NSAIDs). However, you should always inform your prescribing doctor of all medications you are taking.

How long before I might see a reduction in migraines on Mounjaro? Based on the available evidence, improvements in migraine frequency tend to emerge alongside meaningful weight loss, typically from around month two or three. The anti-inflammatory effects of tirzepatide may also contribute over a similar timeframe.

Should I stop my current migraine treatment if Mounjaro helps? No, not without consulting your neurologist or headache specialist. Any changes to preventive migraine medication should be made under medical supervision, even if your attacks become less frequent.

Is Mounjaro suitable specifically for migraine treatment? No. Mounjaro is licensed for weight management (BMI 30 or above, or BMI 27 or above with a weight-related comorbidity) and type 2 diabetes. It is not prescribed specifically for migraine prevention. Any migraine benefit is a secondary effect of metabolic improvement and weight loss.

The relationship between obesity and migraine is well established, and emerging evidence suggests that GLP-1 receptor agonists, including tirzepatide, may help reduce migraine frequency through weight loss, anti-inflammatory effects and CGRP modulation. A 2025 case series in Headache and large pharmacoepidemiological analyses both point toward a protective signal, although dedicated clinical trials are needed before firm conclusions can be drawn.

For patients living with both obesity and migraine, Mounjaro offers the prospect of addressing two burdensome conditions through a single treatment pathway. While it is not a migraine drug, the metabolic transformation it enables may meaningfully reduce attack frequency and improve quality of life for patients whose migraines are driven or worsened by excess weight.